Name: UMIN ID:
Unique ID issued by UMIN | UMIN000011679 |
---|---|
Receipt number | R000013645 |
Scientific Title | Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancer |
Date of disclosure of the study information | 2013/09/08 |
Last modified on | 2016/11/16 09:09:27 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2013/09/08 10:49:28 | ||
2 | Update | 2016/03/08 14:02:46 | Control |
|
3 | Update | 2016/06/28 12:32:23 | UMIN ID1 |
|
4 | Update | 2016/11/16 09:08:58 | Email Name of person sending information Name of person sending information Name of primary person or sponsor Organization |
|
5 | Update | 2016/11/16 09:09:27 | Key inclusion criteria |